Smeland E, Fuskevåg O M, Nymann K, Svendesn J S, Olsen R, Lindal S, Bremnes R M, Aarbakke J
Department of Pharmacology, Institute of Medical Biology, University of Tromsø, Norway.
Cancer Chemother Pharmacol. 1996;37(5):415-22. doi: 10.1007/s002800050406.
To elucidate mechanisms for methotrexate (MTX)-induced renal and hepatic toxicity, we investigated the acute effects of bolus plus continuous infusion of up to 0.4 g/kg 7-hydroxymethotrexate (7-OH-MTX) in the rat. We demonstrate for the first time in any species the occurrence of acute lethal toxicity within a few hours after 7-OH-MTX administration. Serum concentrations of 7-OH-MTX measured at the time of death were 1.4 mM (mean), about one-half of those achieved in some patients after infusion of high-dose MTX (HD-MTX) in the clinic. The data suggest an approximate LD50 (the dose lethal to 50% of the study population) of 0.3 g/kg and a steep dose/lethality curve for 7-OH-MTX. Moreover, acute renal and hepatic toxicity occurred as evidenced by severe morphological findings and increased serum levels of creatinine and liver transaminases. In all rats subjected to continuous infusion of 7-OH-MTX, yellow microscopic precipitations were apparent in the kidney tubules. Crystallization was also seen in bile ducts of the liver in some of the rats. These results further support that the formation of 7-OH-MTX is disadvantageous and that reported attempts to prevent its formation during MTX treatment are warranted.
为阐明甲氨蝶呤(MTX)诱导的肾毒性和肝毒性机制,我们研究了大剂量推注加持续输注高达0.4 g/kg的7-羟基甲氨蝶呤(7-OH-MTX)对大鼠的急性影响。我们首次在任何物种中证明了在给予7-OH-MTX后数小时内出现急性致死毒性。死亡时测得的7-OH-MTX血清浓度为1.4 mM(平均值),约为临床中一些患者输注高剂量MTX(HD-MTX)后所达到浓度的一半。数据表明7-OH-MTX的半数致死剂量(LD50,即对50%研究群体致死的剂量)约为0.3 g/kg,且其剂量/致死率曲线很陡。此外,严重的形态学改变以及血清肌酐和肝转氨酶水平升高表明出现了急性肾毒性和肝毒性。在所有接受7-OH-MTX持续输注的大鼠中,肾小管内可见黄色微观沉淀。部分大鼠的肝内胆管也出现了结晶现象。这些结果进一步支持7-OH-MTX的形成是有害的,并且有必要尝试在MTX治疗期间防止其形成。